$TCRX News
Last published 2mo ago
- 2mo agoTCRXTScan Therapeutics Strategic Update Call - TSCAN THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to T-Scan Therapeutics Strategic Update Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-
- 2mo agoTCRXTScan Therapeutics Strategic Update Call - TSCAN THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to T-Scan Therapeutics Strategic Update Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-
- 2mo agoTCRXTScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid TumorsGlobeNewswireAdvances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100%
- 3mo agoTCRXTScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireFirst patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash
- 3mo agoTCRXTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme MalignanciesGlobeNewswireWALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 4mo agoTCRXTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswireWALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 4mo agoTCRXALLOHA Cohort C Data Presentation - TScan TherapeuticsEarnings Call TranscriptsLadies and gentlemen, thank you for standing by and welcome to the Aloha Cohort C data presentation. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-an
- 4mo agoTCRXTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationGlobeNewswire11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be well-tolerated
- 5mo agoTCRXCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesBusiness WireCollaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan's lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to
- 6mo agoTCRXTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEarly data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026
- 6mo agoTCRXTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingGlobeNewswireWALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 7mo agoTCRX25th Annual Needham Virtual Healthcare ConferenceTSCAN THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for joining us on the third day of the Needham Healthcare Conference. It is my pleasure to have with me today Gavin McMath, CEO of T-SCAN. Gavin, it's great to have you on. I think
- 7mo agoTCRXTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireWALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 7mo agoONCYGILDENGNTCRX+1Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CarePR NewswireUSANewsGroup.com News Commentary — The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by...
- 8mo agoTCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswirePresented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1
- 8mo agoTCRXTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03GlobeNewswireCompleted enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for
- 8mo agoTCRXTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 10mo agoGTBPADCTSTROCRNX+1Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma PipelinesPR NewswireEquity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning...
- 11mo agoTCRXTScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionGlobeNewswireTreatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free
- 11mo agoGTBPGERNKURASLS+1Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsPR NewswireTriple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die...
- 11mo agoTCRXTScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesGlobeNewswireWALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 12mo agoTCRXTScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireReached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA™ Phase 1 heme trial to be presented at the 67th American Society of Hematology (ASH)
- 1y agoTCRXTScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireWALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027GlobeNewswirePositive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development;
- 1y agoTCRXTScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025GlobeNewswireWALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireTwo-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and
- 1y agoTCRXTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoONCYAKYAQTRXTCRX+1New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer BiotechsPR NewswireEquity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is...
- 1y agoTCRXTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireUpdates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second
- 1y agoTCRXTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingGlobeNewswireWALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireWALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market AccessGlobeNewswireWALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswirePresented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201
- 1y agoTCRXTScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceGlobeNewswireWALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% PremiumGlobeNewswireWALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoFCNCATCRXTScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley BankGlobeNewswireWALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and ExpositionGlobeNewswireTo date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities observed and
- 1y agoTCRXTScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive YearsGlobeNewswireWALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development StrategyGlobeNewswireWALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 1y agoTCRXTScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireUpcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on
- 2y agoTCRXTScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and ExpositionGlobeNewswireAll TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS
- 2y agoTCRXTScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual MeetingGlobeNewswireWALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 2y agoTCRXTScan Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 2y agoTCRXTScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireFDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support
- 2y agoTCRXTScan Therapeutics Announces Updates to its Board of DirectorsGlobeNewswireGarry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair
- 2y agoTCRXTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T)
- 2y agoTCRXTScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme MalignanciesGlobeNewswireWALTHAM, Mass, May 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- 2y agoONCYTCRXBMYPDSB+1Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young AdultsPR NewswireUSA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...